U.S. markets open in 1 hour 7 minutes
  • S&P Futures

    4,167.50
    +9.75 (+0.23%)
     
  • Dow Futures

    34,326.00
    +70.00 (+0.20%)
     
  • Nasdaq Futures

    13,390.50
    +87.00 (+0.65%)
     
  • Russell 2000 Futures

    2,233.30
    +7.80 (+0.35%)
     
  • Crude Oil

    66.58
    +0.31 (+0.47%)
     
  • Gold

    1,872.30
    +4.70 (+0.25%)
     
  • Silver

    28.69
    +0.42 (+1.47%)
     
  • EUR/USD

    1.2223
    +0.0067 (+0.55%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.69
    +0.88 (+4.68%)
     
  • GBP/USD

    1.4207
    +0.0069 (+0.49%)
     
  • USD/JPY

    108.9100
    -0.2900 (-0.27%)
     
  • BTC-USD

    45,119.05
    -250.60 (-0.55%)
     
  • CMC Crypto 200

    1,258.81
    +60.89 (+5.08%)
     
  • FTSE 100

    7,056.82
    +23.97 (+0.34%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

  • Oops!
    Something went wrong.
    Please try again later.
Isoray, Inc.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing.

CEO Lori Woods said Fort’s appointment adds key expertise. “I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray.”

Woods concluded, “We believe Donna’s proven dedication to optimizing corporate success will make a valuable contribution as we continue to pursue opportunities to expand Cesium-131 brachytherapy treatment applications throughout the body and build Isoray’s position in our core prostate business.”

Donna Fort’s extensive experience spans both biotechnology and medical device companies with an emphasis in oncology radioactive isotopes and monoclonal antibody technology. Fort has been with five start-up companies, having launched numerous complex multi-disciplinary products, including three radioactive isotopes for cancer.

Fort joins Isoray following nine years with Sirtex Medical, where she held numerous management positions in the U.S. Most recently, she served as Executive Vice President, Sales & Marketing-Asia Pacific. In that capacity, she achieved substantial growth while managing the commercial business in eleven countries. In addition, Fort successfully streamlined efficiencies in the sales process and attained enhanced customer and patient experience by shortening the time to treat.

Fort’s background also includes more than seven years with Johnson & Johnson, where she received numerous sales accolades and was recognized as the top performer in the immunology franchise of Centocor/Janssen. She is a graduate of the Johnson & Johnson Leadership Development Program and was the recipient of numerous leadership team awards.

Commenting on the departure of Senior Vice President of Sales and Marketing Michael Krachon Woods said, “We appreciate Michael’s service to the Company, and we wish him well in his future endeavors.”

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us on LinkedIn and Facebook and follow us on Twitter.

Safe Harbor Statement.

Statements in this news release about Isoray's future expectations, including whether the hiring of Ms. Fort will result in the successful identification and consummation of growth opportunities in the Company’s core prostate business as well as in the treatment of other cancers and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether the anticipated growth opportunities will be identified and achieved. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910